UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation

Mucosal immunology, 2016-11, Vol.9 (6), p.1455-1465

2016

Volltextzugriff (PDF)

Anaemia in inflammatory bowel disease: a population‐based 10‐year follow‐up

Alimentary pharmacology & therapeutics, 2014-01, Vol.39 (1), p.69-76

2014

Volltextzugriff (PDF)

Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?

Digestive diseases (Basel), 2017-01, Vol.35 (1-2), p.74-82

2017

Volltextzugriff (PDF)

A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts

JOURNAL OF CROHNS & COLITIS, 2023, Vol.17 (Suppl. 1), p.I71

2023

Volltextzugriff (PDF)

P882 Regional differences in biologic and surgical treatment of inflammatory bowel disease in Norway 2011–2019

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i999-i1001

2023

Volltextzugriff (PDF)

P376 Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i378-i379

2022

Volltextzugriff (PDF)

P302 Malignancy surveillance in patients with primary sclerosing cholangitis and Inflammatory Bowel Disease – keeping up with international guidelines? A Norwegian cohort study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i331-i332

2022

Volltextzugriff (PDF)

Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation

Journal of hepatology, 2023-10, Vol.79 (4), p.955-966

2023

Volltextzugriff (PDF)

P877 A comparison of vedolizumab and ustekinumab treatment in patients with Ulcerative Colitis after failure of treatment with tumor necrosis factor inhibitor

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1619-i1619

2024

Volltextzugriff (PDF)

P475 Real world data on treatment success and drug persistence in anti-TNF therapy for ulcerative colitis

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S464-S465

2021

Volltextzugriff (PDF)

P407 Thiopurines: use them or lose them? Results of an international survey

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S414-S415

2021

Volltextzugriff (PDF)

P247 Anxiety and depression in newly diagnosed patients with Inflammatory Bowel Disease – Results from the IBSEN III study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i598-i598

2024

Volltextzugriff (PDF)

P1147 Symptoms of irritable bowel syndrome are common in patients in remission from Inflammatory Bowel Disease: Results from an observational population-based cohort study in Norway

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i2055-i2055

2024

Volltextzugriff (PDF)

DOP90 The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD: results after 20 years of follow-up in the IBSEN study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S085-S085

2019

Volltextzugriff (PDF)

P636 Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i555-i555

2022

Volltextzugriff (PDF)

DOP11 A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i71-i73

2023

Volltextzugriff (PDF)

P353 Ulcerative Colitis in the IBSEN III study: Frequent use of biologics and low colectomy rates first year of disease

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i489-i490

2023

Volltextzugriff (PDF)

P920 Gut microbiota at diagnosis is associated with clinical features and future disease course in Inflammatory Bowel Disease: Data from IBSEN III, a new large Norwegian population-based inception cohort

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i1028-i1029

2023

Volltextzugriff (PDF)

P240 Low surgery rates first year after diagnosis in Crohn’s disease; results from a large population-based inception cohort - the IBSEN III study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i393-i394

2023

Volltextzugriff (PDF)

Gut microbiota at diagnosis is associated with clinical features and future disease course in Inflammatory Bowel Disease: Data from IBSEN III, a new large Norwegian population-based inception cohort

Journal of Crohn's and colitis, 2023, Vol.17 (Suppl. 1), p.1028

2023

Volltextzugriff (PDF)

P860 The Costs of Inflammatory Bowel Diseases in High-Income Settings

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i983-i983

2023

Volltextzugriff (PDF)

P154 A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i314-i315

2023

Volltextzugriff (PDF)

P243 Changes in the therapeutic management of inflammatory bowel disease in the biological era – a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study

Journal of Crohn's and colitis, 2020-01, Vol.14 (Supplement_1), p.S267-S267

2020

Volltextzugriff (PDF)

P271 Fecal calprotectin at diagnosis is associated with oral steroid use first year of Inflammatory Bowel Disease

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i309-i310

2022

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(63)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(64)
Tagungsberichte
(5)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation

Anaemia in inflammatory bowel disease: a population‐based 10‐year follow‐up

Does the Introduction of Biosimilars Change Our Understanding about Treatment Modalities for Inflammatory Bowel Disease?

A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts

A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts

P882 Regional differences in biologic and surgical treatment of inflammatory bowel disease in Norway 2011–2019

P376 Switching from intravenous to subcutaneous vedolizumab maintenance treatment; feasibility, safety and clinical outcome

P302 Malignancy surveillance in patients with primary sclerosing cholangitis and Inflammatory Bowel Disease – keeping up with international guidelines? A Norwegian cohort study

Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation

P877 A comparison of vedolizumab and ustekinumab treatment in patients with Ulcerative Colitis after failure of treatment with tumor necrosis factor inhibitor

P475 Real world data on treatment success and drug persistence in anti-TNF therapy for ulcerative colitis

P407 Thiopurines: use them or lose them? Results of an international survey

P247 Anxiety and depression in newly diagnosed patients with Inflammatory Bowel Disease – Results from the IBSEN III study

P1147 Symptoms of irritable bowel syndrome are common in patients in remission from Inflammatory Bowel Disease: Results from an observational population-based cohort study in Norway

DOP90 The impact of spondyloarthritis and joint symptoms on health-related quality of life and fatigue in IBD: results after 20 years of follow-up in the IBSEN study

P636 Work disability after 20 years with Inflammatory Bowel Disease - results from the IBSEN study

DOP11 A novel diagnostic serum protein signature for paediatric Inflammatory Bowel Disease: A discovery and validation study in two independent inception cohorts

P353 Ulcerative Colitis in the IBSEN III study: Frequent use of biologics and low colectomy rates first year of disease

P920 Gut microbiota at diagnosis is associated with clinical features and future disease course in Inflammatory Bowel Disease: Data from IBSEN III, a new large Norwegian population-based inception cohort

P240 Low surgery rates first year after diagnosis in Crohn’s disease; results from a large population-based inception cohort - the IBSEN III study

Gut microbiota at diagnosis is associated with clinical features and future disease course in Inflammatory Bowel Disease: Data from IBSEN III, a new large Norwegian population-based inception cohort

P860 The Costs of Inflammatory Bowel Diseases in High-Income Settings

P154 A novel serum protein signature as biomarker for Inflammatory Bowel Disease: A diagnostic performance and prediction modelling study using data from two independent inception cohorts

P243 Changes in the therapeutic management of inflammatory bowel disease in the biological era – a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study

P271 Fecal calprotectin at diagnosis is associated with oral steroid use first year of Inflammatory Bowel Disease

Suchergebnisse filtern